There is substantial need to improve the outcome of patients with high-risk acute myeloid leukemia (AML). The clinical trial reported here investigated a new approach of up-front allogeneic hematopoietic stem cell transplantation (HSCT), provided a median of 40 days (range 22-74) after diagnosis, in twenty-six consecutive patients with newly-diagnosed high-risk AML characterized by poor-risk cytogenetics (n ¼ 19) or inadequate blast clearance by induction chemotherapy (IC, n ¼ 7). The median age was 49 years (range 17-68). During IC-induced aplasia after the 1st (n ¼ 11) or 2nd (n ¼ 15) cycle, patients received allogeneic peripheral blood stem cells (PBSC) from related (n ¼ 11) or unrelated (n ¼ 15) donors following a fludarabine-based reduced-intensity regimen. Seventeen patients were not in remission before HSCT with a median marrow blast count of 34% (range 6-70). All patients achieved rapid engraftment and went into remission with complete myeloid and lymphatic chimerism. Grades II to IV acute GvHD occurred in 14 (56%) and extensive chronic GvHD was documented in 8 (35%) patients. The probability of disease-free survival was 61% with only three patients relapsing 5, 6 and 7 months after transplantation, respectively. Up-front allogeneic HSCT as part of primary induction therapy seems to be an effective strategy in highrisk AML patients and warrants further investigation.
Introduction
Karyotype is a major prognostic risk factor in patients with acute myeloid leukemia (AML) translating into unfavourable outcome in case of poor-risk cytogenetic aberrations. 1, 2 Several studies have shown that allogeneic hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning rather than autologous HSCT or consolidation chemotherapy results in long-term disease control in this group of patients when achieving a first complete remission. [3] [4] [5] Nevertheless, the complete remission rate achievable is significantly lower than in patients with a more favourable risk profile. In fact, only the minority of AML patients with poor-risk cytogenetics, although having a suitable donor, proceed to HSCT due to refractory disease or infectious complications during induction chemotherapy (IC). 1, 3, 6, 7 Further, new data show that the course of therapy can be estimated as early as two weeks after the initiation of the first course of IC with patients presenting with or more than 10% marrow blasts doing significantly worse than those with a better clearance of blasts. 8 As a result, the chance to obtain a durable remission is considerably low and most patients with poor-risk cytogenetics or failure to achieve blast clearance do not proceed to an allogeneic approach. Together these data indicate that early treatment intensification is warranted in order to provide the potential curative benefit of allogeneic HSCT to the majority of high-risk AML patients.
It is of note, that most of the patients lack a suitable sibling donor. In fact, within the last decade grafts from HLA-identical unrelated donors have been shown to be an acceptable alternative. 9 Additionally, G-CSF mobilized peripheral blood stem cells (PBSC) have become the most widely used graft source. Interestingly, their use seems to be associated with a survival benefit in patients with high-risk disease. 10, 11 We have shown that reduced-intensity conditioning (RIC) followed by allogeneic PBSC applied during aplasia after the first cycle of IC in newly-diagnosed high-risk AML patients is feasible and can result in a sustained disease control. 12 These data prompted us to further evaluate within a prospective trial an early 'up-front HSCT' in 26 patients with newly-diagnosed high-risk AML defined by karyotype and insufficient blast clearance after the first cycle of IC. The results suggest that this approach might be a promising strategy in patients who are unlikely to achieve remission and long-term disease control with conventional allogeneic transplant protocols.
Patients and methods

Study design
The outline of the study is summarized in Figure 1 . Only patients with newly-diagnosed AML were eligible for this prospective study. At diagnosis all patients were treated within the SHG 96 ('Sü ddeutsche Hämoblastosegruppe') trial 13 which was closed in 2002. Since then, the patients have been accrued within the German Study Initiative for Leukemias (DSIL) 2003 trial. An immediate donor-search, either within the family or in volunteer donor registries, was performed at diagnosis irrespective of the expected risk profile. In both studies all patients received at least one cycle of IC. The type of IC varied between both trials as outlined below. Inclusion criteria for up-front allogeneic transplantation were either poor risk cytogenetics and/or bad response to the first cycle of IC defined by X10% marrow blasts on day 15. If a patient met one of those criteria they could enter the up-front allogeneic HSCT trial after providing informed consent. The protocol had been approved by the review board of the medical faculty at the university hospital Dresden. Between 1998 and 2005 twenty-nine consecutive patients fulfilled the study entry criteria and entered the trial (Figure 1 ). Of those, in 26 a suitable donor could be identified within the time frame to provide conditioning during IC-induced aplasia. In 11 out of 26 patients allogeneic HSCT was provided during IC-induced aplasia after the first IC cycle irrespective of response. In 15 out of 26 patients no donor was available at this time point. Therefore, a second cycle was applied and the transplant was performed during the consecutive aplasia again irrespective of the remission status achieved. In the first four patients a DMSO-based i.v. busulfan instead of melphalan was used for conditioning which was at that time evaluated prospectively at our centre. 12, 14 After this program had stopped, the following patients were given i.v. melphalan.
Three out of 29 patients (median age 53 years, all with poorrisk cytogenetics) were given standard myeloablative conditioning (12 Gy TBI/120 mg/kg Cyclophosphamide n ¼ 2, Busulfan 16 mg/kg/ 120 mg/kg Cyclophosphamide n ¼ 1) and allogeneic unrelated (HLA-identical) HSCT in first complete remission, which was obtained after two cycles of IC (n ¼ 2) or an additional cycle (n ¼ 1) of consolidation chemotherapy. The median time from diagnosis to transplant was 115 days (range 93-174). One patient (complex karyotype) died due to early relapse 3 months after HSCT. A second patient (complex karyotype) died due to infectious complications related to severe GvHD (grade IV) 1 months after transplant. One patient (del 11q23) is still alive in sustained remission and without any sign of clinically significant GvHD 56 months after diagnosis.
Patient characteristics
Twenty-six (n ¼ 26) patients with newly-diagnosed AML and poor-risk cytogenetic aberrations (n ¼ 19, complex, 11q23, inv3 or t(3;3), t(3;5), -7 or del 7q, del5q, þ 8, þ 14) or standard risk cytogenetics with minor or no response to the first cycle of IC (n ¼ 7) were included so far (Table 1 ). In fact, 15 patients out of the group with poor-risk cytogenetics had a minor (n ¼ 4, 410% blasts, but less than 50% at diagnosis) or no response (n ¼ 11) to the first cycle of IC. Additionally, in patients UPN 917, 1002, 1101, 1110 and 1131 a FLT-3 internal tandem duplication (ITD) was documented. The median age was 49 years with a range from 17 to 68.
Induction chemotherapy
Eleven patients received one cycle of IC whereas in 15 patients an additional cycle was administered before allografting ( Up-front allogeneic transplant in high-risk AML U Platzbecker et al Donor selection and blood stem cell harvest DNA-based HLA-typing of donor and recipient was performed using high resolution (4 digits) for HLA -A, B, DRB1 and DQB1 and intermediate resolution (2 digits) for HLA-C. As a rule, only one mismatch in nine out of ten alleles was accepted. Six patient-donor pairs had a one-locus HLA mismatch. Donors and patients were sex mismatched in 14 cases, with a female donor for a male recipient in 5 cases. CMV-seropositivity of either donor or recipient was documented in 19 patients. All patients received G-CSF mobilized PBSC from related (n ¼ 11) or unrelated (n ¼ 15) donors as previously described. (Table 1) .
GvHD prophylaxis
Cyclosporin A (CsA) was either administered intravenously at a dose of 3 mg/kg/day or given at an bioequivalent amount of the oral formulation in two divided doses starting on the day before blood stem cell infusion (day À1). The dose of CsA was adjusted to maintain blood levels between 150 and 250 ng/ml. Starting on day 50, oral CsA administration was tapered by 5% weekly if GvHD was inactive. Acute and chronic GvHD were primarily treated with prednisone, CsA or tacrolimus.
Chimerism analyses
Blood samples for overall chimerism were drawn twice weekly during hospital stay and weekly in the out-patient department. Quantitative donor chimerism analysis was done with a short-tandem-repeat (STR) PCR assay. 16 In nine patients we performed detailed chimerism analyses of sorted CD4 þ , CD8 þ , CD56 þ and CD15 þ cells as described before. 16 For this purpose, 40 ml peripheral blood was drawn every four weeks after transplantation. Since earlier studies had shown that donor chimerism of CD3À/CD56 þ NK cells was mainly predictive for the risk of graft-failure, NK subset chimerism was only performed until day 56 after transplantation. 17 In case of a decreasing donor chimerism in all other subsets mentioned above, further analyses were performed in shorter intervals. A marrow sample was taken routinely on day 100, six and twelve months after transplantation or in case of decreasing overall chimerism. A complete remission was defined as less than 5% blasts in the marrow aspirate.
Regimen-related toxicity
Regimen-related toxicity was scored using the Common Toxicity Criteria (CTC) version 3.0 of the National Cancer Institute of the United States (http://ctep.cancer.gov/reporting/ctc.html). Acute and chronic GvHD were diagnosed and graded using established criteria. 18, 19 Supportive care
Tests for cytomegalovirus (CMV) pp65 antigen or polymerase chain reaction (PCR) for CMV DNA were performed weekly. In case of a positive test result, pre-emptive therapy with ganciclovir 5 mg/kg q12 to 24 h was initiated and administered until PCR results became negative. Infectious disease prophylaxis consisted of ciprofloxacin, fluconazole and acyclovir.
Statistical analysis
Estimates of survival and disease-free survival were obtained by the method of Kaplan and Meier where patients were censored at last follow-up if still alive. 20 The incidences of relapse and non-relapse mortality were calculated using cumulative incidence estimates. 21 
Results
Engraftment and chimerism
The median overall duration of aplasia from diagnosis until neutrophil engraftment was 44 days (range 29-75). Rapid engraftment of neutrophils (on day 13, range 8-19; defined as the first of three consecutive days 40.5 Gpt/l) and platelets (on day 15, range 11-32; defined as the first of three consecutive days 450 Gpt/l without platelet support) was achieved and complete donor chimerism was observed in all patients. A complete overall donor chimerism could be documented after a median of 11 days (range 7-24) in all patients. The results of overall and subset chimerism of nine patients are summarized in Figure 2 . All patients experienced a rapid increase of donor chimerism in CD4 þ and CD8 þ T cells. The same was true for NK (CD56 þ /CD3À) cells and mature myeloid cells (CD15 þ ). These data demonstrate that an early complete donor chimerism in all lineages can be achieved with this approach. 
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Regimen-related toxicity (RRT)
Toxicities included mucositis grade I to III (n ¼ 21), aspergillus pneumonia (n ¼ 7), septicemia (n ¼ 2) and thrombotic-thrombocytopenic purpura (TTP, n ¼ 1). CMV-DNA or pp65 antigen was detectable in nine patients. Four patients died while being in remission 2, 4, 20 and 38 months after HSCT from aspergillus pneumonia (n ¼ 3) or intestinal bleeding (n ¼ 1) occurring after GvHD of the gut (n ¼ 3) or lung (n ¼ 1), respectively. The cumulative incidence of death without relapse was 4% at day 100 and 15% at 24 months. Grades II to IV acute GvHD occurred in 14 (54%) out of 26 evaluable patients. As shown in Table 2 grade III acute GvHD was observed in 3 (12%) patients, and two patients (8%) had grade IV acute GvHD mainly involving the gut. There was no detectable difference in the incidence and severity of acute GvHD between patients receiving a graft from related compared to unrelated donors (grade II-IV GvHD related donor: 54%, unrelated donor: 57%). All but one patients (96%) survived beyond day 100, and 16 out of 25 evaluable patients (64%) developed chronic GvHD that was extensive in 8 (32%) patients. So far, 9 patients have been able to discontinue all immunosuppressive drugs.
Relapse
Hematological relapse occurred in 3 out of 26 patients 5, 6 and 7 months after transplant. The cumulative incidences of relapse and non-relapse mortality are shown in Figure 3 . One patient (UPN 1133) achieved a remission after a second transplant from the same donor but died due to pneumonia as a result of immunosuppressive treatment of steroid refractory GvHD of the gut. Another patient (UPN 848) with relapse also achieved remission after a second transplantation but died like the third patient (UPN1008) from infectious complications 6 and 8 months after transplantation, respectively.
Survival
The probabilities of overall survival (OS) and disease-free survival (DFS) were 61%, respectively (Figure 3 ). There was no significant correlation between disease-free and overall survival and host CMV-seropositivity, CD34 þ cell dose, age and female donor of a male host (data not shown). After a median follow-up of 22 months (range 7-85) for surviving patients 19 (73%) out of 26 patients are alive and in remission. No patient survived after hematological relapse. The Karnofsky performance index of the 19 surviving patients ranged between 70 and 100% (median 80%) by the time of last follow-up.
Discussion
We have shown here for the first time that an up-front allogeneic transplant approach using reduced intensity conditioning during IC might be a promising strategy in order to achieve sustained disease control in high-risk AML defined by karyotype and primary response to IC. It is of note that more than 50% of the patient population was not in remission when conditioning was started. Additionally, five patients presented with a FLT-3 ITD which renders them at further risk of treatment failure. 22, 23 Given this and the presence of poor-risk cytogenetics in the majority of patients the probability of relapse is very low compared to other studies demonstrating the profound antileukemic effect of our approach. Most of the data published so far do not suggest that RIC might work in advanced AML patients. [24] [25] [26] Therefore, we believe that allogeneic graft-versusleukemia effects are more likely to succeed early after diagnosis with a limited stage of residual disease before secondary drug resistance as a result of repetitive administration of chemotherapy becomes a major issue. Therefore in this trial conditioning was started during chemotherapy-induced aplasia.
Several studies have investigated the role of allogeneic HSCT in the treatment of high-risk AML. 5 In all studies HSCT was applied after achieving complete remission, which occurs only in about 50% of this patient population. Further, the studies differ with regard to the time point of allogeneic transplantation. In the MRC trial patients were assigned as late as after two cycles of IC followed by two cycles of consolidation. As a result only the minority of eligible patients underwent HSCT mostly due to failure to achieve remission, relapse or death due to infectious complications. 1 This might be one explanation for the dismal outcome reported. In contrast, the EORTC trial in younger AML patients could clearly show a benefit of HSCT in patients with high-risk cytogenetics translating into a 4-years disease-free survival of 43%, which was age-dependent. Again, around 25% of patients assigned for HSCT with a sibling donor did not receive a transplant due to toxicity or early relapse. 4 Additionally, in most of the prospective studies a conventional HSCT following myeloablative conditioning was performed. Recently, transplant protocols using reduced-intensity conditioning have been reported to be associated with less treatment-related mortality in patients with myeloid malignancies. 17, 25, [27] [28] [29] The use of reduced-intensity conditioning might be one explanation for the moderate extramedullary toxicity observed in our study. Nevertheless, three patients died with pulmonary aspergillosis. In fact, all suffered from severe acute or chronic GvHD requiring intensive immunosuppression including high-dose steroids. Although the antifungal treatment options have improved over time, the prognosis of these patients is still limited. 30 Early studies by the Seattle group in patients with chemotherapy refractory AML have shown that allogeneic HSCT is able to provide long-term disease control in a subset of patients. 31 A recent report demonstrated the feasibility of front-line allogeneic transplant in a small cohort of untreated AML/MDS patients above the age of 60 years. 32, 33 In newly-diagnosed AML, the biology of the disease does mostly not permit a delay of treatment until a donor is identified. Therefore, we think that our approach is a reasonable strategy in order to apply a cytoreductive therapy, which provides a time frame for a successful donor search. Our promising results are in line with a recently published study by Schmid et al. who investigated a sequential approach of a combination of cytoreductive chemotherapy followed by a TBI-based RIC in patients with high-risk AML. 34 Although the study design differed from the one presented here sustained remission was achieved even in chemotherapy refractory patients, which again emphasizes the importance and role of the graft versus leukemia effect.
Since a related donor is not available in most of the cases the fast identification of a suitable unrelated donor is a major prerequisite for our approach. In the current study we were able to use the 'fast search program' of the German bone marrow donor center (DKMS). Indeed, the median time from diagnosis to unrelated transplantation was 46 days, which clearly shows that it is possible to receive a suitable unrelated graft within this time interval.
In conventional treatment protocols only 50% of our patient population would have been evaluated as candidates for an allogeneic HSCT given the bad response to IC. Therefore, the data presented here may be regarded as promising. Of course only a prospective comparison can clearly prove the clinical Up-front allogeneic transplant in high-risk AML U Platzbecker et al 711 Up-front allogeneic transplant in high-risk AML
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benefit of the approach outlined in this report. The repetitive administration of further chemotherapy cycles in order to achieve remission might select for chemo-resistant leukemia clones thereby decreasing their susceptibility to the immune response. These data are in agreement with the French AML study group demonstrating a better outcome for patients transplanted early after completion of standard IC. 35 In fact, in this study the median time from diagnosis to transplantation was 120 days, which is three times longer than reported here.
One might argue that the rate of acute GvHD in this series seems to be considerable but we believe that early graft-versusleukemia effects can only be harnessed by less intensive immunosuppressive prophylaxis regimens. This is supported by the observation that two out of three patients who relapsed had no evidence of chronic, which might be a prerequisite for long-term disease control in this patient population. The use of cyclosporine as the only post-grafting immunosuppression led to a rapid achievement of complete donor chimerism in T and NK cells. Fast engraftment of donor effector cells might have helped to the institution of early graft-versus leukemia effects and the low risk of relapse observed in this cohort of patients with highrisk AML. The concept of the current protocol is incorporated into a prospective multicenter trial of the German Study Initiative for Leukemias (DSIL, 2003) in which patients with high-risk AML defined by karyotype, FLT-3 ITD status and blast clearance in response to first cycle of IC are randomized to receive either an up-front allogeneic HSCT versus transplantation performed after 2-3 cycles of chemotherapy and consecutive hematological reconstitution. The study design will allow to prove, whether up-front transplantation strategies allow to achieve superior survival rates in patients with high-risk AML. 
